Methods for treating and diagnosing disease
AssigneeFibrostatin, S.L.
InventorsJuan Saus, Fernando Revert, Ramón Merino, Jesús Merino, Francisco Revert-Ros
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for the diagnosis and/or treatment of chronic kidney disease, immune complex-mediated GN, rheumatoid arthritis, and pulmonary fibrosis, and methods for identifying compounds for such therapeutic use.
Claims19
A method for treating pulmonary fibrosis (PF), comprising administering to a subject in need thereof an amount effective of an inhibitor of 77 kD GPBP to treat the PF.
A method for treating chronic kidney disease (CKD), comprising administering to a subject in need thereof an amount effective of an inhibitor of 77 kD GPBP to treat the CKD.
A method for treating immune complex-mediated GN, comprising administering to a subject in need thereof an amount effective of an inhibitor of 77 kD GPBP to treat the immune complex-mediated GN.
A method for diagnosing rheumatoid arthritis (RA) or pulmonary fibrosis (PF) comprising
- (a) contacting a plasma sample from a subject at risk of RA or PF with a GPBP-binding molecule that binds to 77 kD GPBP under conditions to promote selective binding of the GPBP-binding molecule to the GPBP;
- (b) detecting complex formation between the GPBP-binding molecule and the 77 kD GPBP in the plasma sample;
- (c) comparing an amount of complex formed between the GPBP-binding molecule and the GPBP in the plasma sample to control;
- and
- (d) diagnosing the subject as having RA or PF based on the comparison, or providing the comparison to an entity for diagnosis of RA or PF.
A method for diagnosing CKD or immune complex-mediated GN, comprising
- (a) contacting a plasma sample from a subject at risk of CKD or immune complex-mediated GN with a GPBP-binding molecule that binds to 77 kD GPBP under conditions to promote selective binding of the GPBP-binding molecule to the GPBP;
- (b) detecting
- (i) complex formation between the GPBP-binding molecule and the 77 kD GPBP in the plasma sample;
- and
- (ii) determining the subject's plasma level of C reactive protein (CRP)
- (c) comparing
- (i) an amount of complex formed between the GPBP-binding molecule and the GPBP in the plasma sample to control;
- and
- (ii) an amount of CRP in the subject's plasma to control;
- and
- (d) diagnosing the subject as having CKD or immune complex-mediated GN based on the comparisons, or providing the comparisons to an entity for diagnosis of CKD or immune complex-mediated GN.
A method for identifying compounds to treat CKD, immune complex-mediated GN, and/or PF, comprising contacting a 77 kD GPBP-77 kD GPBP substrate binding complex with one or more test compounds under binding conditions, wherein those test compounds that displace 77 kD GPBP from the binding complex are candidate compounds for treating CKD, immune complex-mediated GN, and/or PF.
A method for identifying compounds to treat CKD, immune complex-mediated GN, and/or PF, comprising contacting a 77 kD GPBP-substrate under binding conditions with
- (a) one or more test compounds;
- and
- (b) 77 kD GPBP;
- wherein those test compounds that outcompete 77 kD GPBP for binding to the 77 kD GPBP-binding substrate are candidate compounds for treating CKD, immune complex-mediated GN, and/or PF.
Dependencies are inferred from the claim text.